Graph showing omega-3 supplementation and systemic vasc

Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration. Rezende FA, Lapalme E, Qian CX, Smith LE, SanGiovanni JP, Sapieha P - Am. J. Ophthalmol. (2014) Bottom Line: Secondary outcomes were plasma VEGF-A and central foveal thickness.Patients receiving omega-3s (group 1) had significantly lower levels of vitreal VEGF-A (141.11 ± 61.89 pg/mL) when compared with group 2 (626.09 ± 279.27 pg/mL; P = .036) and group 3 (735.48 ± 216.43 pg/mL; P = .013), but similar levels to group 4 (235.81 ± 33.99 pg/mL; P = .215).This study demonstrated that omega-3 supplementation combined with anti-VEGF treatment is associated with decreased vitreal VEGF-A levels in wet AMD patients. View Article: PubMed Central - PubMed Affiliation: Department of Ophthalmology, Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal, Quebec, Canada. Electronic address: frezendef@hotmail.com. Show MeSH Major Antibodies, Monoclonal, Humanized/administration & dosage* Dietary Supplements* Fatty Acids, Omega-3/administration & dosage* Vascular Endothelial Growth Factor A/antagonists & inhibitors/metabolism* Vitreous Body/metabolism* Wet Macular Degeneration/diagnosis/etiology/therapy* Minor Aged Aged, 80 and over Angiogenesis Inhibitors/administration & dosage Bevacizumab Dose-Response Relationship, Drug Female Fluorescein Angiography Follow-Up Studies Fundus Oculi Humans Intravitreal Injections Male Prospective Studies Tomography, Optical Coherence Treatment Outcome Visual Acuity Related in: MedlinePlus	© Copyright Policy - open-access Related In: Results - Collection License Show All Figures getmorefigures.php?uid=PMC4389631&req=5 Figure 3: Graph showing omega-3 supplementation and systemic vascular endothelial growth factor (VEGF) A concentrations in wet age-related macular degeneration and control patients. Plasma VEGF levels demonstrating no significant difference between group 4 (control; n = 8) and group 1 (anti-VEGF plus omega-3; n = 9; P = .7361), group 2 (anti-VEGF alone; n=6; P=.6194), and group 3 (treatment naïve, starting on anti-VEGF; n = 7; P = .9474, t test). Mentions: Analysis of plasma levels of VEGF-A revealed no significant change between groups (P = .736; Figure 3). Similarly, although values for CFT tended toward improvement, no significant benefit was noted with omega-3 supplementation in the sample population investigated in this pilot study (P = .211; Figure 4).

Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration.

Rezende FA, Lapalme E, Qian CX, Smith LE, SanGiovanni JP, Sapieha P - Am. J. Ophthalmol. (2014)

Bottom Line: Secondary outcomes were plasma VEGF-A and central foveal thickness.Patients receiving omega-3s (group 1) had significantly lower levels of vitreal VEGF-A (141.11 ± 61.89 pg/mL) when compared with group 2 (626.09 ± 279.27 pg/mL; P = .036) and group 3 (735.48 ± 216.43 pg/mL; P = .013), but similar levels to group 4 (235.81 ± 33.99 pg/mL; P = .215).This study demonstrated that omega-3 supplementation combined with anti-VEGF treatment is associated with decreased vitreal VEGF-A levels in wet AMD patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal, Quebec, Canada. Electronic address: frezendef@hotmail.com.

Show MeSH

Related in: MedlinePlus

Graph showing omega-3 supplementation and systemic vascular endothelial growth factor (VEGF) A concentrations in wet age-related macular degeneration and control patients. Plasma VEGF levels demonstrating no significant difference between group 4 (control; n = 8) and group 1 (anti-VEGF plus omega-3; n = 9; P = .7361), group 2 (anti-VEGF alone; n=6; P=.6194), and group 3 (treatment naïve, starting on anti-VEGF; n = 7; P = .9474, t test).

Related In: Results - Collection

License

Show All Figures

getmorefigures.php?uid=PMC4389631&req=5

Figure 3: Graph showing omega-3 supplementation and systemic vascular endothelial growth factor (VEGF) A concentrations in wet age-related macular degeneration and control patients. Plasma VEGF levels demonstrating no significant difference between group 4 (control; n = 8) and group 1 (anti-VEGF plus omega-3; n = 9; P = .7361), group 2 (anti-VEGF alone; n=6; P=.6194), and group 3 (treatment naïve, starting on anti-VEGF; n = 7; P = .9474, t test).

Mentions: Analysis of plasma levels of VEGF-A revealed no significant change between groups (P = .736; Figure 3). Similarly, although values for CFT tended toward improvement, no significant benefit was noted with omega-3 supplementation in the sample population investigated in this pilot study (P = .211; Figure 4).